Breaking News

Catalent Biologics, IVERIC bio Ink Mfg. Pact

Paragon Gene Therapy, part of Catalent Biologics, will provide materials for preclinical and Phase 1/2 trials for IVERIC’s gene therapy product candidates

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

IVERIC bio, Inc. and Catalent Biologics, have entered into an agreement for production and manufacture of GMP-grade adeno-associated virus (AAV) vector for IVERIC bio’s gene therapy product candidates, IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related retinal diseases. IVERIC bio expects to initiate Phase 1/2 trials for IC-100 in 2020 and IC-200 in 1H21. IVERIC bio has engaged Paragon Gene Therapy, part...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters